FDA has added warning information about a vision loss risk to labels for Ozempic Wegovy Zepbound and other GLP-one medicines Reports have surfaced about vision problems Regulator action followed these reports Related coverage included several media outlets Mounjaro was also cited in related news This directive came out on a specific day Safety concerns prompted this step Vision issues are the focus Drug label changes are now active This applies to certain weight management aids More information is available Officials issued the advisory It is an important update Consider the new caution These medications need review